FDA Asks for More Data on Ide-cel as Potential Multiple Myeloma Therapy
The U.S. Food and Drug Administration (FDA) asked for more information from Bristol Myers Squibb and Bluebird Bio as it considers a…
Myeloma
Cell Protein Analysis May Predict Multiple Myeloma Response to Treatment
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively treat people with …
FDA Approves Darzalex Faspro as Injection Therapy for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved Janssen‘s new formulation of daratumumab — a subcutaneous or under-the-skin injection treatment called Darzalex Faspro…
Actemra May Treat Severe COVID-19 Infections in Myeloma Patients, Case Report Suggests
Actemra (tocilizumab), a medicine approved for certain types of arthritis, may be effective in treating severe infections with the new coronavirus in…
Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak
FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect…
Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove…
Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple…
Bristol Myers, Bluebird Bio Seek FDA Approval of Ide-cel to Treat Advanced Multiple Myeloma
Bristol Myers Squibb and Bluebird Bio are seeking U.S. approval of their lead investigational CAR T-cell therapy —…
Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide)…
Oncopeptides’ Accelerated Approval Filing for Melflufen in US Unimpeded by COVID-19
Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in…
